Therapeutic resistance in lung cancer

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 5, 2006, Pages 753-777

  Nadkar, Aalok ^a   Pungaliya, Chirag ^a   Drake, Kenneth ^a   Zajac, Ewa ^a   Singhal, Sharad S ^a   Awasthi, Sanjay ^a  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

Drug resistance; Glutathione conjugates; Lung cancer; Radiation; RALBP1; RLIP76; Transport

Indexed keywords

ANTINEOPLASTIC AGENT; GLUTATHIONE DERIVATIVE; HEAT SHOCK PROTEIN; PROTEIN RALBP1; PROTEIN RLIP76; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; DRUG RESISTANCE; HUMAN; LUNG CANCER; RADIOSENSITIVITY; REVIEW; STRESS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CELL CYCLE; DNA; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GTPASE-ACTIVATING PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; RADIATION TOLERANCE;

EID: 33846379526     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.5.753     Document Type: Review

References (144)

1. KRUG LM: Vaccine therapy for small cell lung cancer. Semin. Oncol. (2004) 31:112-116.
2. ARRIAGADA R, LE PECHOUX C, PIGNON JP: Resected non-small cell lung cancer: need for adjuvant lymph node treatment? From hope to reality. Lung Cancer (2003) 42:S57-S64.
3. HOFFMAN PC, MAUER AM, VOKES EE: Lung cancer. Lancet (2000) 355(9202):479-485.
4. CAYUELA A, RODRIGUEZ-DOMINGUEZ S, LOPEZ-CAMPOS JL, OTERO CANDELERA R, RODRIGUEZ MATUTES C: Joinpoint regression analysis of lung cancer mortality, Andalusia 1975-2000. Ann. Oncol. (2004) 15(5):793-796.
5. HENSCHKE CI, SHAHAM D, YANKELEVITZ DF et al.:- CT screening for lung cancer: significance of diagnoses in its baseline cycle. Clin. Imaging (2006) 30(1):11-15.
6. MULSHINE JL: New developments in lung cancer screening. J. Clin. Oncol. (2005) 23(14):3198-3202.
7. WOODS RL, FOX RM, TATTERSALL MH: Treatment of small cell bronchogenic carcinoma with VM-26. Cancer Treat. Rep. (1979) 63(11-12):2011-2013.
8. TRANUM BL, HAUT A, RIVKIN S et al.: A phase II study of methyl CCNU in the treatment of solid tumors and lymphomas: a Southwest Oncology Group study. Cancer (1975)35(4):1148-1153.
9. KRAUSS S, LOWENBRAUN S, BARTOLUCCI A, BUCHANAN R, BIRCH R: Alternating non-cross-resistant drug combinations in the treatment of metastatic small-cell carcinoma of the lung. Cancer Clin. Trials (1981) 4(2):147-153.
10. HARPER PG, DALLY MB, GEDDES DM, SPIRO SG, SMYTH JF, SOUHAMI RL: Epipodophyllotoxin (VP16-213) in small cell carcinoma of the Bronchus resistant to initial combination chemotherapy. Cancer Chemother. Pharmacol. (1982) 7(2-3):179-180.
11. FUKS JZ, AISNER J, CARNEY DN et al.: A phase II trail of vindesine in patients with refractory small-cell carcinoma of the lung. Am. J. Clin. Oncol. (1982) 5(1):49-52.
12. ARONEY RS, BELL DR, CHAN WK, DALLEY DN, LEVI JA: Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung. Cancer (1982) 49(12):2449-2454.
13. LEMAISTRE CF, KNIGHT WA 3rd: High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors. Invest. New Drugs (1983) 1(4):321-329.
14. CURT GA, CARNEY DN, COWAN KH et al.: Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N. Engl. J. Med. (1983) 308(4):199-202.
15. SHOEMAKER RH, CURT GA, CARNEY DN: Evidence for multidrug-resistant cells in human tumor cell populations. Cancer Treat. Rep. (1983) 67(10):883-888.
16. NATALE RB, WITTES RE: Alternating combination chemotherapy regimens in small-cell lung cancer. Semin. Oncol. (1985) 12(1 Suppl 2):7-13.
17. FELD R, EVANS WK, COY P et al.: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J. Clin. Oncol. (1987) 5(9):1401-1409.
18. EVANS WK, FELD R, MURRAY N et al.: Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann. Intern. Med. (1987) 107(4):451-458.
19. WOLF M, HAVEMANN K, HOLLE R et al.: Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial. J. Clin. Oncol. (1987) 5(12):1880-1889.
20. TANNOCK IF: New perspectives in combined radiotherapy and chemotherapy treatment. Lung Cancer (1994) 10(Suppl. 1):S29-S51.
21. CARNEY DN: The biology of lung cancer. Curr. Opin. Pulm. Med. (1995) 1(4):271-277.
22. CARNEY DN, GAZDAR AF, NAU M, MINNA JD: Biological heterogeneity of small cell lung cancer. Semin. Oncol. (1985) 12(3):289-303.
23. ENGELHOLM SA, SPANG-THOMSEN M, VINDELOV LL, BRUNNER N: Effect of melphalan on growth curves and cell cycle distribution of four human small cell carcinomas of the lung grown in nude mice. Exp. Cell Biol. (1986) 54(3):138-148.
24. BRANDES A, SOESAN M, FIORENTINO MV: Medical treatment of high grade malignant gliomas in adults: an overview. Anticancer Res. (1991) 11(2):719-727.
25. SINGHAL SS, SINGHAL J, SHARMA R et al.: Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells. Int. J. Oncol. (2003) 22(2):365-375.
26. AWASTHI S, SINGHAL SS, SINGHAL J, CHENG J, ZIMNIAK P, AWASTHI YC: Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. Int. J. Oncol. (2003) 22(4):713-720.
27. AWASTHI S, SINGHAL SS, SINGHAL J, YANG Y, ZIMNIAK P, AWASTHI YC: Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity. Int. J. Oncol (2003) 22(4):721-732.
28. BERMAN R, GUSTERSON B, STEEL GG: Resistance to alkylating agents and tumour differentiation in xenografts of small cell lung cancer. Br. J. Cancer (1985) 51(5):653-658.
29. CURT GA, JOLIVET J, CARNEY DN et al.: Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin. Invest. (1985) 76(4):1323-1329.
30. AWASTHI S, SHARMA R, SINGHAL SS, ZIMNIAK P, AWASTHI YC: RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab. Dispos. (2002) 30(12):1300-1310.
31. AWASTHI S, SINGHAL SS, SHARMA R, ZIMNIAK P, AWASTHI YC: Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and ryrosine kinase signaling and drug resistance. Int. J. Cancer (2003) 106(5):635-646.
32. STUCKLER D, SINGHAL J, SINGHAL SS, YADAV S, AWASTHI YC, AWASTHI S: RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer. Cancer Res. (2005) 65(3):991-998.
33. AWASTHI S, SINGHAL SS, YADAV S et al.: RLIP76 is a major determinant of radiation sensitivity. Cancer Res. (2005) 65(14):6022-6028.
34. JAKOBY WB: The glutathione S-transferases: a group of multifunctional detoxification proteins. Adv. Enzymol. Relat. Areas Mol. Biol. (1978) 46:383-414.
35. HAYES JD, PULFORD DJ: The glutathione 5-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. (1995) 30(6):445-600.
36. FANG YZ, YANG S, WU G: Free radicals, antioxidants, and nutrition. Nutrition (2002) 18(10):872-879.
37. ETHIER SP: Signal transduction pathways: the molecular basis for targeted therapies. Semin. Radiat. Oncol. (2002) 12(3 Suppl. 2):3-10.
38. KING TC, ESTALILLA OC, SAFRAN H: Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. Semin. Radiat. Oncol. (1999) 9(2 Suppl. 1):4-11.
39. CAMPLING BG, EL-DEIRY WS: Clinical implications of p53 mutations in lung cancer. Methods Mol. Med. (2003) 75:53-77.
40. FUJIWARA T, GRIMM EA, MUKHOPADHYAY T, ZHANG WW, OWEN-SCHAUB LB, ROTH JA: Induction of chemo-sensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. (1994) 54(9):2287-2291.
41. GOLDSMITH ME, GUDAS JM, SCHNEIDER E, COWAN KH: Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J. Biol. Chem. (1995) 270(4):1894-1898.
42. ZHAO H, SPITZ MR, TOMLINSON GE, ZHANG H, MINNA JD, WU X: Gamma-radiation-induced G2 delay, apoptosis, and p53 response as potential susceptibility markers for lung cancer. Cancer Res. (2001) 61(21):7819-7824.
43. VIKTORSSON K, DE PETRIS L, LEWENSOHN R: The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun. (2005) 331(3):868-880.
44. WANG Y, BLANDINO G, GIVOL D: Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytoroxic effect of radiation and doxorubicin. Oncogene (1999) 18(16):2643-2649.
45. NAKANISHI Y, KAWASAKI M, BAI F et al.: Expression of p53 and glutathione S-transferase-π relates to clinical drug resistance in non-small cell lung cancer. Oncology (1999) 57(4):318-323.
46. SLEBOS RJ, RODENHUIS S: The molecular genetics of human lung cancer. Eur. Respir. J. (1989) 2(5):461-469.
47. KOO HM, MONKS A, MIKHEEV A et al.: Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res. (1996) 56(22):5211-5216.
48. VOLM M, STAMMLER G: Retinoblastoma (Rb) protein expression and resistance in squamous cell lung carcinomas. Anticancer Res. (1996) 16(2):891-894.
49. O'LOUGHLIN C, HEENAN M, COYLE S, CLYNES M: Altered cell cycle response of drug-resistant lung carcinoma cells to doxorubicin. Eur. J. Cancer (2000) 36(9):1149-1160.
50. MINEMOTO Y, UCHIDA S, OHTSUBO M et al.: Loss of P53 induces M-phase retardation following G2 DNA damage checkpoint abrogation. Arch. Biochem. Biophys. (2003) 412(1):13-19.
51. PAUL EC, QUARONI A: Identification of a 102 kDa protein (cytocentrin) immunologically related to keratin 19, which is a cytoplasmically derived component of the mitotic spindle pole. J. Cell. Sci. (1993) 106(Pt 3):967-981.
52. MORINAKA K, KOYAMA S, NAKASHIMA S et al.: Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis. Oncogene (1999) 18(43):5915-5922.
53. IKEDA M, ISHIDA O, HINOI T, KISHIDA S, KIKUCHI A: Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. J. Biol. Chem. (1998) 273(2):814-821.
54. ROSSE C, L'HOSTE S, OFFNER N, PICARD A, CAMONIS J: RLIP, an effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J. Biol. Chem. (2003) 278(33):30597-30604.
55. BATTISTA P, PIZZICANNELLA G, VITULLO P, PALMIROTTA R, MARIANI-COSTANTINI R: The epidermal growth factor family in pulmonary carcinoids: immunohisrochemical evidence of growth-promoting circuits. Mod. Pathol. (1993) 6(2):162-166.
56. ZHAO J, KIM JE, REED E, LI QQ: Molecular mechanism of antitumor activity of taxanes in lung cancer (review), Int. J. Oncol. (2005) 27(1):247-256.
57. NICAMHLAOIBH R, HEENAN M, CLEARY I et al.: Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int. J. Cancer (1999) 82(3):368-376.
58. IKEGAKI N, KATSUMATA M, MINNA J, TSUJIMOTO Y: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. (1994) 54(1):6-8.
59. SARTORIUS UA, KRAMMER PH: Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int. J. Cancer (2002) 97(5):584-592.
60. REEVE JG, XIONG J, MORGAN J, BLEEHEN NM: Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer (1996) 73(10):1193-1200.
61. ZHANG Y, FUJITA N, TSURUO T: p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int. J. Cancer (1999) 83(6):790-797.
62. PREWITT TW, MATTHEWS W, CHAUDHRI G, POGREBNIAK HW, PASS HI: Tumor necrosis factor induces doxorubicin resistance to lung cancer cells in vitro. J. Thorac. Cardiovasc. Surg. (1994) 107(1):43-49.
63. KIM JY, LEE S, HWANGBO B et al.: NF-κB activation is related to the resistance of lung cancer cells to TNF-α-induced apoptosis. Biochem. Biophys. Res. Commun. (2000) 273(1):140-146.
64. CHENG Q, LEE HH, LI Y, PARKS TP, CHENG G: Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene (2000) 19(42):493G-4940.
65. ANDRIOLLO M, FAVIER A, GUIRAUD P: Adriamycin activates NF-κB in human lung carcinoma cells by IκBα degradation. Arch. Biochem. Biophys. (2003) 413(1):75-82.
66. CHENG JZ, SHARMA R, YANG Y et al.: Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress. J. Biol. Chem. (2001) 276(44):41213-41223.
67. SINGHAL SS, AWASTHI YC, AWASTHI S: Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res. (2006) 66(4):2354-2360.
68. SKACEL N, MENON LG, MISHRA PJ et al.: Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment. J. Biol. Chem. (2005) 280(24):22721-22731.
69. TESEI A, RICOTTI L, DE PAOLA F, AMADORI D, FRASSINETI GL, ZOLI W: In vitro schedule-dependent interactions between the multitargeted antifolate LY-231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin. Cancer Res. (2002) 8(1):233-239.
70. SUZUKI T, NISHIO K, TANABE S: The MRP family and anticancer drug metabolism. Curr. Drug Metab. (2001) 2(4):367-377.
71. BINASCHI M, ZUNINO F, CAPRANICO G: Mechanism of action of DNA topoisomerase inhibitors. Stem Cells (1995) 13(4):369-379.
72. BECK WT, DANKS MK: Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin. Cancer Biol. (1991) 2(4):235-244.
73. WANG JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. (2002) 3(6):430-440.
74. GIACCONE G, GAZDAR AF, BECK H, ZUNINO F, CAPRANICO G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. (1992) 52(7):1666-1674.
75. KANZAWA F, SUGIMOTO Y, MINATO K et al.: Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. (1990) 50(18):5919-5924.
76. SUGIMOTO Y, TSUKAHARA S, OH-HARA T, LIU LF, TSURUO T: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. (1990) 50(24):7962-7965.
77. CAPRANICO G, SUPINO R, BINASCHI M et al.: Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance. Mol. Pharmacol. (1994) 45(5):908-915.
78. FELDHOFF PW, MIRSKI SE, COLE SP, SULLIVAN DM: Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res. (1994) 54(3):756-762.
79. DINGEMANS AM, WITLOX MA, STALLAERT RA, VAN DER VALK P, POSTMUS PE, GIACCONE G: Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin. Cancer Res. (1999) 5(8):2048-2058.
80. LONG BH, WANG L, LORICO A, WANG RC, BRATTAIN MG, CASAZZA AM: Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Cancer Res. (1991) 51(19):5275-5283.
81. YAMAZAKI K, ISOBE H, HANADA T et al.: Topoisomerase IIα content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother. Pharmacol. (1997) 39(3):192-198.
82. ZOCHBAUER-MULLER S, GAZDAR AF, MINNA JD: Molecular pathogenesis of lung cancer. Annu. Rev. Physiol. (2002) 64:681-708.
83. ZOCHBAUER-MULLER S, MINNA JD, GAZDAR AF: Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist (2002) 7(5):451-457.
84. VINEIS P, CAPORASO N: Tobacco and cancer: epidemiology and the laboratory. Environ. Health Perspect. (1995) 103(2):156-160.
85. TSAI CM, CHANG KT, LI L, PERNG RP, YANG LY: Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn. J. Cancer Res. (2000) 91(2):213-222.
86. PETERS GJ, VAN MOORSEL CJ, LAKERVELD B, SMID K et al.: Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines. Int. J. Oncol. (2006) 28(1):237-244.
87. RAY SD, PATEL D, WONG V, BAGCHI D: In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen- induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH-636 grape seed proanthocyanidin extract. Res. Commun. Mol. Pathol. Pharmacol. (2000) 107(1-2):137-166.
88. ZIENOLDDINY S, CAM PA D, LIND H et al.: Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis (2006) 27(3):560-567.
89. GANDHI V, HUANG P, PLUNKETT W: Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk. Lymphoma (1994) 14(Suppl 2):3-9.
90. FRIEDBERG EC: Relationships between DNA repair and transcription. Annu. Rev. Biochem. (1996) 65:15-42.
91. LAGE H, DIETEL M: Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. (1999) 125(3-4):156-165.
92. XUE Y, NICHOLSON WL: The two major spore DNA repair pathways, nucleotide excision repair and spore photoproduct lyase, are sufficient for the resistance of Bacillus subtilis spores to artificial UV-C and UV-B but not to solar radiation. Appl. Environ. Microbiol. (1996) 62(7):2221-2227.
93. HILL BT, BELLAMY AS, METCALFE S, HEPBURN PJ, MASTERS JR, WHELAN RD: Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro. Invest. New Drugs (1984) 2(1):29-33.
94. BRUNO T, LEONETTI C, ALOE S et al.: Levels of expression of hRPB11, a core subassembly subunit of human RNA polymerase II, affect doxorubicin sensitivity and cellular differentiation. FEBS Lett. (1998) 427(2):241-246.
95. MODRICH P: Strand-specific mismatch repair in mammalian cells. J. Biol. Chem. (1997) 272(40):24727-24730.
96. JIRICNY J, NYSTROM-LAHTI M: Mismatch repair defects in cancer. Curr. Opin. Genet. Dev. (2000) 10(2):157-161.
97. KARRAN P: Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis (2001) 22(12):1931-1937.
98. FINK D, AEBI S, HOWELL SB: The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. (1998) 4(1):1-6.
99. KAINA B, OCHS K, GROSCH S et al.: BER, MGMT, and MMR in defense against alkylation-induced genotoxiciry and apoptosis. Prog. Nucleic Acid Res. Mol. Biol. (2001) 68:41-54.
100. EGYHAZI S, BERGH J, HANSSON J, KARRAN P, RINGBORG U: Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur. J. Cancer (1991) 27(12):1658-1662.
101. MATTERN J, EICHHORN U, KAINA B, VOLM M: O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int. J. Cancer (1998) 77(6):919-922.
102. OBERLI-SCHRAMMLI AE, JONCOURT F, STADLER M et al.: Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int. J. Cancer (1994) 59(5):629-636.
103. NITURE SK, DONEANU CE, VELU CS, BAILEY NI, SRIVENUGOPAL KS: Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem. Biophys. Res. Commun. (2005) 337(4):1176-1184.
104. BOULTON SJ, JACKSON SP: Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways. EMBO J. (1996) 15(18):5093-5103.
105. AYORA S, PIRUAT JI, LUNA R et al.: Characterization of two highly similar Rad51 homologs of Physcomitrella patens. J. Mol. Biol. (2002) 316(1):35-49.
106. OMORI S, TAKIGUCHI Y, SUDA A et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA Repair (2002) 1(4):299-310.
107. CHEAH PL, LOOI LM: P53: an overview of over ovo decades of study. Malays. J. Pathol. (2001) 23(1):9-16.
108. SUN Y: p53 and its downstream proteins as molecular targets of cancer. Mol. Carcinog. (2006) 45(6):409-415.
109. AVIS IM, JETT M, BOYLE T et al.: Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest. (1996) 97(3):806-813.
110. ADAMS GP, WEINER LM: Monoclonal antibody therapy of cancer. Nat. Biotechnol. (2005) 23(9):1147-1157.
111. ROSS JS, SCHENKEIN DP, PIETRUSKO R et al.: Targeted therapies for cancer 2004. Am. J. Clin. Pathol. (2004) 122(4):598-609.
112. TSAI CM, CHANG KT, WU LH et al.: Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res. (1996) 56(1):206-209.
113. TSAI CM, LEVITZKI A, WU LH et al.: Enhancement of chemosensitiviry by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. (1996) 56(5):1068-1074.
114. TSAI CM, CHANG KT, LI L, PERNG RP, YANG LY: Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn. J. Cancer Res. (2000) 91(2):213-222.
115. VOLM M, KOOMAGI R, MATTERN J: Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. (1996) 16(1):213-217.
116. VOLM M, MATTERN J, KOOMAGI R: Expression of platelet-derived endothelial cell growth factor in non-small cell lung carcinomas: relationship to various biological factors. Int. J. Oncol. (1998) 13(5):975-979.
117. ALBERTS DS, GARCIA DJ: Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix. Semin. Oncol. (1994) 21(4 Suppl. 7):37-46.
118. FUKUOKA K, SAIJO N: Antimitotic agents. Can To Kagaku Ryoho (1997) 24(11):1519-1525.
119. VAN ARK-OTTE J, SAMELIS G, RUBIO G, LOPEZ SAEZ JB, PINEDO HM, GIACCONE G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol. Rep. (1998) 5(1):249-255.
120. ACHIWA H, SATO S, SHIMIZU S et al.: Analysis of β-tubulin gene alteration in human lung cancer cell lines. Cancer Lett. (2003) 201(2):211-216.
121. OHTA S, NISHIO K, KUBOTA N et al.: Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn. J. Cancer Res. (1994) 85(3):290-297.
122. KYU-HO HAN E, GEHRKE L, TAHIR SK et al.: Modulation of drug resistance by α-tubuliri in paclitaxel-resistant human lung cancer cell lines. Eur. J. Cancer (2000) 36(12):1565-1571.
123. GONCALVES A, BRAGUER D, KAMATH K et al.: Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. USA (2001) 98(20):11737-11742.
124. OHTA S, NISHIO K, KUBO S et al.: Characterisation of a vindesine-resistant human small-cell lung cancer cell line. Br. J. Cancer (1993) 68(1):74-79.
125. COLE SP, PINKOSKI MJ, BHARDWAJ G, DEELEY RG: Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br. J. Cancer (1992) 65(4):498-502.
126. HAN EK, TAHIR SK, CHERIAN SP, COLLINS N, NG SC: Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer (2000) 83(1):83-88.
127. SETHI T, RINTOUL RC, MOORE SM et al.: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. (1999) 5(6):662-668.
128. OSHITA F, KAMEDA Y, IKEHARA M et al.: Increased expression of integrin β1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. (2002) 22(2B):1065-1070.
129. FRIDMAN R, GIACCONE G, KANEMOTO T, MARTIN GR, GAZDARAR MULSHINE JL: Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA (1990) 87(17):6698-6702.
130. BELANGER MM, ROUSSEL E, COUET J: Up-regulation of caveolin expression by cytotoxic agents in drug-sensitive cancer cells. Anticancer Drugs (2003) 14(4):281-287.
131. TROOST J, LINDENMAIER H, HAEFELI WE, WEISS J: Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol. Pharmacol. (2004) 66(5):1332-1339.
132. LI JY, VOLKNANDT W, DAHLSTROM A et al.: Axonal transport of ribonucleoprotein particles (vaults). Neuroscience (1999) 91(3):1055-1065.
133. SHIMAMOTO Y, SUMIZAWA T, HARAGUCHI M et al.: Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol. Rep. (2006) 15(3):645-652.
134. LAURENCOT CM, SCHEFFER GL, SCHEPER RJ, SHOEMAKER RH: Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer (1997) 72(6):1021-1026.
135. VOLM M, MATTERN J, KOOMAGI R: Expression of lung resistance-related protein (LRP) in non-small cell lung carcinomas of smokers and non-smokers and its predictive value for doxorubicin resistance. Anticancer Drugs (1997) 8(10):931-936.
136. KICKHOEFER VA, RAJAVEL KS, SCHEFFER GL, DALTON WS, SCHEPER RJ, ROME LH: Vaults are up-regulated in multidrug-resistant cancer cell lines. J. Biol. Chem. (1998) 273(15):8971-8974.
137. HUFFMAN KE, COREY DR: Major vault protein does not play a role in chemoresistance or drug localization in a non-small cell lung cancer cell line. Biochemistry (2005) 44(7):2253-2261.
138. VOLM M, POMMERENKE EW: Associated expression of protein kinase C with resistance to doxorubicin in human lung cancer. Anticancer Res. (1995) 15(2):463-466.
139. DING L, WANG H, LANG W, XIAO L: Protein kinase C-ε promotes survival of lung cancer cells by suppressing apoptosis through deregulation of the mitochondrial caspase pathway. J. Biol. Chem. (2002) 277(38):35305-35313.
140. CLARK AS, WEST KA, BLUMBERG PM, DENNIS PA: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance. Cancer Res. (2003) 63(4):780-786.
141. NISHIO K, SUGIMOTO Y, KASAHARA K et al.: Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum (II). Int. J. Cancer (1992) 50(3):438-442.
142. BROGNARD J, DENNIS PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ. (2002) 9(9):893-904.
143. JOSEPH MG, BANERJEE D, KOCHAW, FELD R, STITT LW, CHERIAN MG: Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer (2001) 92(4):836-842.
144. RICHARDS EH, HICKEY E, WEBER L, MASTER JR: Effect of overexpression of the small heat shock protein HSP-27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res. (1996) 56(10):2446-2451.